Alnylam Establishes New Research Program on Delivery of RNAi Therapeutics at MIT's Center for Cancer Research

May 09, 2007

Cubist Reports First Quarter 2007 Results

April 18, 2007

Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer

April 17, 2007

athenahealth Joins With the Iowa Medical Society; Offers On-Demand Clinical and Practice Management Services to Physicians

April 10, 2007

Bioconnect Systems Completes $8M Series A Financing

April 05, 2007

VISICU WINS TOP INNOVATOR OF THE YEAR AWARD

April 03, 2007

Saint Joseph's Opens First eICU(R) Facility in Southeast

March 30, 2007

Momenta Pharmaceuticals to Present At the Cowen and Company 27th Annual Health Care Conference

March 08, 2007

athenahealth to Present at 27th Annual Cowen and Company Healthcare Conference

March 08, 2007

INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics

March 07, 2007

Alnylam to Webcast at the Cowen and Company 27th Annual Health Care Conference

March 07, 2007

Sirtris Pharmaceuticals, Inc. Files for Initial Public Offering

March 01, 2007

Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs

March 01, 2007

Alnylam Scientist Awarded Two Industry Honors

February 28, 2007

Cubist Pharmaceuticals to Present at the Leerink Swann & Company Novel Antibiotic Conference

February 28, 2007

CodeRyte Named a Finalist in the 2007 SIIA Codie Awards

January 31, 2007

Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations

January 09, 2007

Alnylam and Inex Form Strategic Technology Alliance to Discover and Develop RNAi Therapeutics with Lipid-Based Delivery Formulations

January 09, 2007

Cubist Pharmaceuticals Announces Fourth Quarter 2006 U.S. Net Product Revenues of $56.2 Million and Full Year 2006 U.S. Net Product Revenues of $189.5 Million

January 08, 2007

Alnylam Announces Key Product and Business Goals for 2007

January 08, 2007

Alnylam Announces Key Product and Business Goals for 2007

January 08, 2007

TWO OF COLORADO'S PREMIER CARDIOLOGY GROUPS SELECT ATHENAHEALTH'S WEB-BASED EMR AND REVENUE CYCLE MANAGEMENT SERVICES

December 20, 2006

ATHENAHEALTH AND AGILENCE HEALTH ADVISORS FORGE ALLIANCE; TARGET NEW YORK AND NEW JERSEY PHYSICIAN AND HOSPITAL MARKETS

December 18, 2006

Alnylam Announces Closing of Common Stock Offering

December 15, 2006

TRIANGLE ORTHOPAEDIC ASSOCIATES SELECTS ATHENAHEALTH'S WEB-BASED PRACTICE MANAGEMENT SERVICE

December 14, 2006

Alnylam Announces Proceeds of Common Stock Offering

December 12, 2006

Alnylam Announces Public Offering of 4,700,000 Shares of Common Stock

December 11, 2006

Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program

December 05, 2006

Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in China to AstraZeneca

December 04, 2006

Sirtris Pharmaceuticals obtains exclusive rights to key sirtuin technology from MIT

November 30, 2006

Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection

November 28, 2006

Sirtris Pharmaceuticals: Resveratrol reduces fat and boosts endurance by activation of SIRT1, first aging gene shown to accelerate human metabolism

November 16, 2006

NORTHERN NEW ENGLAND METROPOLITAN MEDICAL RESPONSE SYSTEM AND ATHENAHEALTH PILOT NEW EMERGENCY RESPONSE MODEL

November 15, 2006

Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics

November 11, 2006

Thomson acquires NexCura:Patient information and communications added to Healthcare Solutions

November 07, 2006

athenahealth Joins with the Arkansas Medical Society; Offers Clinical and Practice Management Services to Physicians

November 07, 2006

Alnylam and Yale University Scientists Demonstrate Therapeutic Silencing of Disease Target Associated with Acute Lung Injury Using RNAi

November 06, 2006

Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2006

November 03, 2006

Alnylam Pharmaceuticals Reports Third Quarter 2006 Financial Results

November 02, 2006

Research published in Nature by Sirtris scientists is first demonstration in mammals that resveratrol, a sirtuin activator, can treat diseases of aging, such as diabetes. Sirtris Pharmaceuticals doses first diabetes patient in human clinical study.

November 01, 2006

Minnesota Hospital Outreach Lab Outsources Accounts Receivable Management to Per-Se Technologies

October 31, 2006

ATHENAHEALTH JOINS WITH WASHINGTON STATE MEDICAL ASSOCIATION TO HELP IMPROVE THE FINANCIAL AND CLINICAL PERFORMANCE OF THE STATE'S MEDICAL PRACTICES

October 27, 2006

Alnylam to Webcast Conference Call Discussing Third Quarter 2006 Financial Results

October 26, 2006

Sirtris Pharmaceuticals to Present at the C.E. Unterberg Towbin Life Sciences Conference, October 30th, 2006

October 25, 2006

ATHENAHEALTH FORMS STRATEGIC ALLIANCE WITH LONE STAR MSO TO HELP TEXAS PHYSICIANS BETTER MANAGE THEIR PRACTICES AND IMPROVE COLLECTIONS

October 24, 2006

Alnylam Announces Progress in Pre-Clinical Hypercholesterolemia RNAi Therapeutic and microRNA Programs

October 23, 2006

Cubist Pharmaceuticals Reports Third Quarter 2006 Results and First Profitable Quarter; GAAP Basic and Diluted Net Income $0.09 Per Share; Net Product Revenues $50.3 Million, up 66% vs. 3Q05

October 18, 2006

Alnylam Announces Progress in Pre-clinical Programs at the 36th Annual Society for Neuroscience Meeting

October 16, 2006

Alnylam Initiates Phase I Clinical Study of Inhaled Formulation of ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection

October 11, 2006

Alnylam Notified of Defense Appropriation Funding for Ongoing Development of RNAi Therapeutics

October 04, 2006

Sirtris Announces Clinical Results from Phase 1 Trials of SRT501, a Sirtuin Therapeutic, Company Initiates Phase 1b Study in Type 2 Diabetes Patients

October 04, 2006

Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics for Biological Threats

September 28, 2006

Sirtris Pharmaceuticals CEO to Speak at Technology Review's Emerging Technologies Conference at MIT on September 28th, 2006

September 26, 2006

US PATENT OFFICE RE-AFFIRMS VISICU’S eICU® PATENT

September 26, 2006

ATHENAHEALTH APPOINTS JAMES MACDONALD AS CHIEF OPERATING OFFICER

September 25, 2006

Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML); Collaboration to Focus on RNAi Therapeutics Targeting the JC Virus

September 20, 2006

ATHENAHEALTH NAMED AS ONE OF NEW ENGLAND'S FASTEST GROWING COMPANIES FOR THE SECOND STRAIGHT YEAR

September 18, 2006

Sirtris Pharmaceuticals Hires Mike Jirousek as SVP of Research

September 12, 2006

Sirtris Pharmaceuticals to Present at Think Equity Conference September 13th, 2006

September 07, 2006

Alnylam Awarded Federal Grant to Develop RNAi Therapeutics for Pandemic Flu

September 06, 2006

MOSES CONE HEALTH SYSTEM CONTINUES TRADITION OF PATIENT CENTRIC CARE WITH eICU® PROGRAM

July 27, 2006

VISICU Reports Second Quarter Results

July 27, 2006

Alnylam Pharmaceuticals Reports Second Quarter 2006 Financial Results; Increasing Revenue Drives Improvement in Year-over-Year Financials

July 26, 2006

Cleveland Clinic Physicians Use Advanced Visualization Technology

July 25, 2006

athenahealth introduces Healthcare industry's first economically sustainable, Service-based EMR offering for Medical Practices

July 25, 2006

Momenta Pharmaceuticals and Sandoz Sign Exclusive Collaboration to Develop Complex Generics and Follow-On Versions of Biotechnology Drugs

July 25, 2006

Sirtris Pharmaceuticals to Present at 5th InternationalMetabolic Diseases Drug Discovery World Summit

July 20, 2006

Cubist Pharmaceuticals Reports Second Quarter 2006 Results; Total Revenues $47.8 Million; Net Product Revenues $45.7 Million, up 78% Vs. 2Q05; GAAP Loss $0.09 Per Share; Non-GAAP Income $0.06 Per Share

July 19, 2006

Alnylam Receives New Issued U.S. Patent Broadly Covering Small Interfering RNAs and Strengthens Leadership in Intellectual Property for RNAi Therapeutics

July 18, 2006

Alnylam Announces Collaboration with University of Texas Southwestern Medical Center to Discover RNAi Therapeutics for Hypercholesterolemia; Collaboration to Focus on PCSK9, a Key Gene Involved in Metabolism of LDL-Cholesterol

July 17, 2006

Eclipsys Partners with athenahealthSM to Deliver Unique Ambulatory Care Solution

July 17, 2006

Alnylam and INEX Accelerate Collaboration on Systemic Delivery of RNAi Therapeutics; Positive Results for Systemic RNAi Support Advancement to Next Phase of Collaboration

July 17, 2006

Remote ICU Saves Lives in Intensive Care

July 10, 2006

ATHENAHEALTH RETAINS TOP RANKING IN THREE AMBULATORY BILLING AND SCHEDULING CATEGORIES ACCORDING TO KLAS 2006 MID-YEAR REPORT CARD

June 29, 2006

ATHENAHEALTH ON PACE TO SAVE OHIO PHYSICIANS OVER $80 MILLION IN AVERTED CLAIM DENIALS FROM HEALTH INSURERS

June 23, 2006

Rib-X Pharmaceuticals Raises $50 Million in Series C Financing

June 20, 2006

ATHENAHEALTH PARTNERS WITH NEW HAMPSHIRE MEDICAL SOCIETY TO HELP IMPROVE THE FINANCIAL AND CLINICAL PERFORMANCE OF THE STATE'S MEDICAL PRACTICES

June 14, 2006

ATHENAHEALTH APPOINTS RICHARD N. FOSTER TO BOARD OF DIRECTORS

June 07, 2006

Sirtris Announces First Phase 1 Trial of a Sirtuin Therapeutic

June 07, 2006

ATHENAHEALTH'S NEW WEB-BASED EMR SERVICE TO INCLUDE DIRECT ELECTRONIC CONNECTIVITY WITH LOCAL PHARMACIES

May 30, 2006

VISICU’S eICU® PROGRAM COMING TO ST. JOSEPH HEALTH SYSTEM

May 16, 2006

SISTERS OF MERCY HEALTH SYSTEM

May 02, 2006

Sirtris Pharmaceuticals Secures $37 Million in Financing

April 20, 2006

Sirtris Pharmaceuticals to present at BioCentury Future Leaders in the Biotech Industry Conference 2006

April 15, 2006

Alnylam Announces Appointment of John Maraganore, Ph.D., to Biotechnology Industry Organization's Board of Directors

April 13, 2006

Alnylam To Collaborate with United States Army on RNAi Therapeutics for Biodefense Threats

April 12, 2006

U.S. PATENT OFFICE ISSUES NOTICE OF INTENT TO ALLOW ALL 26 AMENDED CLAIMS OF VISICU’S eICU® PATENT AFTER REEXAMINATION

April 11, 2006

Sirtris Pharmaceuticals to present at SG Cowen 26th Annual Health Care Conference

March 31, 2006

Scientists 'silence gene' to slash cholesterol levels

March 27, 2006

Sirtris Pharmaceuticals’ Science of Sirtuins Highlighted by Scientific American

February 13, 2006

ATHENAHEALTH POSTS RECORD GROWTH IN 2005

February 07, 2006

RMS Partners With IntelliCare to Implement “KEY to Better Health”, A Renal Disease Management Program Focused on Chronic Kidney Disease (CKD)

January 24, 2006

Alnylam Announces Allowance of Additional U.S. Patent Broadly Covering RNAi Therapeutics

January 24, 2006

Alnylam Announces Public Offering of Common Stock

January 23, 2006

Remote ICU care keeps an eye out

January 18, 2006

Alnylam Announces Allowance of U.S. Patent Broadly Covering RNAi Therapeutics

January 17, 2006

Alnylam Initiates Second Phase I Clinical Study of ALN-RSV01

December 19, 2005

Alnylam Announces Pandemic Flu as Next Development Program

December 14, 2005

Treasures in the Trash

December 12, 2005

Sirtris Pharmaceuticals Hires Peter Elliott as SVP, Head of Development

November 30, 2005

Cubist Pharmaceuticals to Present at Lazard Capital Markets Life Sciences Conference

November 23, 2005

Cubist Pharmaceuticals Expands U.S. Hospital Sales Organization

November 22, 2005

Alnylam Added to NASDAQ Biotechnology Index

November 21, 2005

FDA Accepts CUBICIN(R) sNDA and Grants Priority Review

November 17, 2005

Alnylam Announces Progress in Pre-clinical Programs at the 35th Annual Society for Neuroscience Meeting; Pre-clinical Data from Parkinson's Disease, Huntington's Disease, and Neuropathic Pain Programs

November 15, 2005